April 8, 2024

Global Indices GIFT Nifty: 22660 +38 Hangseng: 16711 -12 Dow: 38904 + 307 S&P 500: 5204 +57 Nasdaq: 16248 +199 USD / INR: 83.28 Brent Crude: 89.47 GOLD: 2343.60 FII Net (05-04-2024): +1659 DII Net (05-04-2024): – 3370

by

Global Indices
GIFT Nifty: 22660 +38
Hangseng: 16711 -12
Dow: 38904 + 307
S&P 500: 5204 +57
Nasdaq: 16248 +199
USD / INR: 83.28
Brent Crude: 89.47
GOLD: 2343.60
FII Net (05-04-2024): +1659
DII Net (05-04-2024): – 3370

Please follow and like us:
fb-share-icon
Tweet
Pin Share

Related posts:

No related posts.

Tags:

Comments are closed.

You may also like

June 10, 2024
by

The National Stock Exchange (NSE) had decided to introduce One Paisa tick size for all stocks below the trading price of ₹250 per share, according to a circular on NSE dated May 24. This change will be applicable from TODAY! All securities – except ETFs – under EQ, BE, BZ, BO, RL and AF series with security price below ₹250 will have tick size of ₹0.01 as against the current tick size of ₹0.05. The tick size determined for securities in T+1 settlement will also be applicable for T+0 settlement FinancialNews #StockMarket $ The National Stock Exchange (NSE) had decided to introduce One Paisa tick size for all stocks below the trading price of ₹250 per share, according to a circular on NSE dated May 24. This change will be applicable from TODAY! All securities – except ETFs – under EQ, BE, BZ, BO, RL and AF series with security price below ₹250 will have tick size of ₹0.01 as against the current tick size of ₹0.05. The tick size determined for securities in T+1 settlement will also be applicable for T+0 settlement FinancialNews #StockMarket $

The National Stock Exchange (NSE) had decided to introduce One Paisa tick size for all stocks below the trading price...

October 7, 2024
by

NATCO PHARMA: CO ANNOUNCES THAT MYLAN PHARMA INC. AND NOVO NORDISK HAVE REACHED A SETTLEMENT OF THE U.S. PATENT LITIGATION RELATED TO GENERIC OZEMPIC (SEMAGLUTIDE). #FinancialNews #Financial MarketTrends   https://earnfree.in/latest NATCO PHARMA: CO ANNOUNCES THAT MYLAN PHARMA INC. AND NOVO NORDISK HAVE REACHED A SETTLEMENT OF THE U.S. PATENT LITIGATION RELATED TO GENERIC OZEMPIC (SEMAGLUTIDE). #FinancialNews #Financial MarketTrends   https://ift.tt/jmZBx8V

NATCO PHARMA: CO ANNOUNCES THAT MYLAN PHARMA INC. AND NOVO NORDISK HAVE REACHED A SETTLEMENT OF THE U.S. PATENT LITIGATION...